U.S. PREVENTIVE SERVICES TASK FORCE LUNG CANCER SCREENING RECOMMENDATION: WHAT CAN YOU EXPECT?

MICHAEL LEFEVRE, MD, MSPH
PROFESSOR AND VICE CHAIR
DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE
UNIVERSITY OF MISSOURI
PAST CHAIR, USPSTF
This presentation will discuss a recommendation of the U.S. Preventive Services Task Force (USPSTF). Although I served on the Task Force at the time of the release of this recommendation, not all views expressed may not reflect the process and recommendations of the USPSTF. For the current findings and recommendations of the USPSTF, please see: www.uspreventiveservicestaskforce.org.
WHAT IS SCREENING?

- Testing asymptomatic individuals for the presence of a disease
WHEN SHOULD WE SCREEN?

- Prevalence of asymptomatic disease justifies effort
- Accurate and acceptable screening test is available
- Intervention in the asymptomatic phase changes the outcome
- Benefits of improved outcomes outweigh the harms of testing and treatment
FACTS ABOUT THE USPSTF?

- The USPSTF is a government committee
- Positive recommendations for preventive services (grades A and B) by the USPSTF must be covered by Medicare
- Negative recommendations (grade D) are not covered by Medicare or insurance companies
- The USPSTF does not consider costs in its recommendations
U.S. PREVENTIVE SERVICES TASK FORCE

• The U.S. Preventive Services Task Force is an independent, volunteer panel of national experts in prevention and evidence-based medicine.

• The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services.
THE USPSTF STEPS: BRIEF AND GENERIC

• Assess the evidence across the analytic framework, synthesizing the assessment of each key question:
  • Judge the **certainty** of the estimate of benefits and harms
  • Judge the **magnitude** of both benefits and harms
  • Determine and judge the **balance of benefits and harms**: the **magnitude of net benefit**
THE USPSTF STEPS: BRIEF AND GENERIC

• If evidence is not sufficient (low certainty), letter grade is “I”
  • In the context of insufficient evidence, the USPSTF does not use “expert opinion”
• If evidence is sufficient, assign a letter grade:
  • A, B, C or D – reflecting both the certainty and magnitude of net benefit
## Grades of Recommendation

<table>
<thead>
<tr>
<th>Certainty of net benefit</th>
<th>Magnitude of net benefit</th>
<th>Moderate</th>
<th>Small</th>
<th>Zero/Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Substantial</td>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td>B</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>Low</td>
<td>I - Insufficient Evidence</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BREAST CANCER SCREENING
FACTS ABOUT BREAST CANCER?

• Prior to the development of mammography screening, most women diagnosed with breast cancer died of their disease
• The incidence of breast cancer in the U.S. is rising
• Mammography reduces the rate of breast cancer deaths by about 50%
• A majority of the increase in the incidence of breast cancer reflects an increase in non-invasive cancers (ductal carcinoma in situ)
Breast Cancer Incidence and Mortality per 100,000
FACTS ABOUT LUNG CANCER?

• The rate of lung cancer is rising in the U.S.
• Advances in treatment have significantly reduced the likelihood that an individual diagnosed with lung cancer will survive the disease
• More people die of lung cancer in the U.S. than breast, prostate and colon cancers combined
• Screening chest x-rays in smokers significantly reduces their likelihood of dying of lung cancer
SCREENING FOR LUNG CANCER

U.S. PREVENTIVE SERVICES TASK FORCE
LUNG CANCER IS IMPORTANT

• Leading cause of cancer related death.
• ~160,000 deaths per year in the U.S.
CANCER DEATHS PER 100,000

Women: Lung, Breast/Prostate, Colon
Men: Lung, Breast/Prostate, Colon
LUNG CANCER IS IMPORTANT

- More deaths than breast cancer, prostate cancer and colon cancer combined
LUNG CANCER IS IMPORTANT

• Tobacco related in 85-90%
NATURAL HISTORY

- Poor prognosis:
  - nearly 90% with lung cancer die of it.
- 5-year survival for all stages: approximately 16%.
LUNG CANCER INCIDENCE AND MORTALITY

Age-Adjusted Rates
By Data Type
Lung and Bronchus, All Ages, All Races, Both Sexes
1975–2010

Year of Diagnosis/Death
Rate per 100,000

SEER Incidence
U.S. Mortality
CXR SCREENING FOR LUNG CANCER

• CXR: 2 trials
  • Mayo Lung Project
  • Prostate, Lung, Colon, Ovarian Screening Trial (PLCO); 1993 - 2001
CXR SCREENING

- Prostate, Lung, Colon, Ovarian Screening Trial (PLCO); 1993 – 2001
  - Males and females ages 55-74 from general population (with a subset of current/former smokers).
    - 77,445 randomized to PA CXR annually.
    - 77,456 randomized to usual care.
  - Evaluation of abnormal tests was done by participants providers.
  - 13-year follow-up.
  - Good-quality.
PLCO

- PLCO results: high-risk population (6-year follow-up)
  - Incidence: RR 1.0 (95% CI; 0.88-1.13)
  - Lung cancer mortality: RR 0.94 (95% CI; 0.81-1.10)
SCREENING WITH LOW DOSE CT

- LDCT: 4 (of 7 total) RCTs with published results in both trial arms.
  - NLST
  - DANTE
  - DLCST
  - MILD: we ultimately agreed should not influence decision
Figure 3. Meta-Analysis of Lung Cancer Mortality

<table>
<thead>
<tr>
<th>Study, year</th>
<th>F/u (yrs)</th>
<th>In*</th>
<th>Co*</th>
<th>Mean age (yrs)</th>
<th>Mean pack-years</th>
<th>Screening times (years)</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLST, 2011</td>
<td>6.5</td>
<td>247</td>
<td>309</td>
<td>61.4</td>
<td>56</td>
<td>0, 1, 2</td>
<td>0.80 (0.73 to 0.93)</td>
</tr>
<tr>
<td>59% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DANTE, 2009</td>
<td>2.8</td>
<td>527</td>
<td>637</td>
<td>64 vs. 65</td>
<td>47.3 vs. 47.2</td>
<td>0, 1, 2, 3, 4</td>
<td>0.83 (0.45 to 1.54)</td>
</tr>
<tr>
<td>100% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLCST, 2012</td>
<td>4.8</td>
<td>154</td>
<td>112</td>
<td>58</td>
<td>36.4 vs. 35.9</td>
<td>0, 1, 2, 3, 4</td>
<td>1.37 (0.63 to 2.97)</td>
</tr>
<tr>
<td>56% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall (I-squared = 0.0%, p = 0.406)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.81 (0.72 to 0.91)</td>
</tr>
</tbody>
</table>

*Per 100,000 person-years
## Meta-Analysis of All-Cause Mortality

<table>
<thead>
<tr>
<th>Study, year</th>
<th>F/u (yrs)</th>
<th>In*</th>
<th>Co*</th>
<th>Mean age (yrs)</th>
<th>Mean pack-years</th>
<th>Screening times (yrs)</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLST, 2011</td>
<td>6.5</td>
<td>1142</td>
<td>1216</td>
<td>61.4</td>
<td>56</td>
<td>0, 1, 2</td>
<td>0.93 (0.86 to 0.99)</td>
</tr>
<tr>
<td>59% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DANTE, 2009</td>
<td>2.8</td>
<td>1212</td>
<td>1433</td>
<td>64 vs. 65</td>
<td>47.3 vs. 47.2</td>
<td>0, 1, 2, 3, 4</td>
<td>0.85 (0.56 to 1.27)</td>
</tr>
<tr>
<td>100% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLCST, 2012</td>
<td>4.8</td>
<td>625</td>
<td>429</td>
<td>58</td>
<td>36.4 vs. 35.9</td>
<td>0, 1, 2, 3, 4</td>
<td>1.46 (0.99 to 2.15)</td>
</tr>
<tr>
<td>56% male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.02 (0.78 to 1.33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-squared</td>
<td>61.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p = 0.077</td>
</tr>
</tbody>
</table>

**Figure 4** Meta-Analysis of All-Cause Mortality
WHO WAS ENROLLED?

**NLST**
- N=53,454
- > 30 pack-year history
- Mean age = 61.4

**DLCST**
- N=4104
- >20 pack-years
- Mean age = 57.9 yrs
LUNG CANCER IS IMPORTANT

• In the three referenced trials of high risk smokers in the previous meta-analysis, in the control groups during the follow-up period there were:
  • 3078 total deaths
  • 1058 deaths from lung cancer (34% of all deaths)

• Contrast that to the ERSPC where over long term follow-up there were:
  • 20,026 total deaths
  • 522 deaths from prostate cancer (2.6% of all deaths)
SCREENING HELPS

• Per 1000 individuals in the target group, 17 will die of lung cancer over an average of 6.5 years

• With 3 annual screens, can avert 3-4 of those deaths
HARMS

- False positive rate and risks of diagnostic testing
- Radiation
- Overdiagnosis
- Psychological harms, including smoking behavior
- Incidental findings
FALSE POSITIVE SCREEN

• First round of screening: 1000 people screened: 250 positive screens
  • 96% false positive
  • After 3 annual screens, number of individuals with at least one positive screen rises to 390
FALSE POSITIVE SCREEN

- In NLST, a high percentage of false positives resolved with subsequent imaging
  - 8 of the 250 positive screens will have an invasive biopsy to show that they do NOT have cancer
  - Of 17,053 positive results, there were 612 complications and 6 deaths after diagnostic procedure
    - (i.e. approximately 1 in 5000 people screened who do not have lung cancer will die because they were screened in contrast to 15-20 in 5000 who will have lung cancer death averted)
RADIATION

• LDCT radiation ranged from 0.61 to 1.5 mSv per scan
  • Mammogram 0.7 mSv
  • Head CT 1.7 mSv

• Cumulative radiation still a concern
  • F/U scans full dose, not low dose
OVERDIAGNOSIS

- Post recommendation, using NLST data, Patz et al reported:
  - Probability that a lung cancer diagnosed on screening is an overdiagnosis is 18.5%
  - Number of overdiagnoses to prevent one death is 1.38
- These estimates are probably high
OTHER HARMs

• Psychological harms: overall, no significant impact on quality of life.

• Smoking behavior: no compelling data suggesting either better or worse quit rates

• Incidental findings: 7.5% in NLST had clinically significant, non-lung cancer findings
CISNET MODELING FOR LUNG CANCER SCREENING
WHY MODELING?

- No trial data for ANY screening test compare screening across the continuum of the age ranges recommended for screening to no screening
## Model Results

### 55-80-30-15

<table>
<thead>
<tr>
<th></th>
<th>Average 5 models</th>
<th>Lower bound</th>
<th>Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer deaths averted</td>
<td>497</td>
<td>177</td>
<td>862</td>
</tr>
<tr>
<td>Life-years gained</td>
<td>5,250</td>
<td>2,020</td>
<td>10,153</td>
</tr>
<tr>
<td>Screening CT scans</td>
<td>287,000</td>
<td>272,000</td>
<td>301,000</td>
</tr>
<tr>
<td>Full dose CT</td>
<td>43,000</td>
<td>23,175</td>
<td>50,100</td>
</tr>
<tr>
<td>Surgery/biopsy for benign lesions</td>
<td>910</td>
<td>825</td>
<td>955</td>
</tr>
<tr>
<td>Overdiagnosed cancers</td>
<td>190</td>
<td>72</td>
<td>426</td>
</tr>
<tr>
<td>Radiation related lung CA death</td>
<td>24</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
B RECOMMENDATION

• The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.
IMPLEMENTATION CAVEATS

- Low risk population
- Smoking cessation counseling
- Shared decision making
- Standardization of LDCT screening and f/u abnormal findings
- Registry
LUNG CANCER INCIDENCE AND MORTALITY: WILL IT CHANGE?
QUESTIONS?